Browsing by Author "Mitrakas, L."
Now showing items 1-4 of 4
-
The combination of lanreotide 90 mg plus dexamethasone in the treatment of hormonerefractory prostate cancer (HRPCA)
Mitsogiannis, I.; Oeconomou, A.; Gravas, S.; Mitrakas, L.; Tzortzis, V.; Moutzouris, G.; Melekos, M. (2007) -
Endothelin-1 overexpression: a potential biomarker of unfavorable prognosis in non-metastatic muscle-invasive bladder cancer
Mitrakas, L.; Gravas, S.; Karasavvidou, F.; Dimakopoulos, G.; Moutzouris, G.; Tzortzis, V.; Koukoulis, G.; Papandreou, C.; Melekos, M. (2015)Endothelin-1 (ET-1) is a multifunctional peptide exerting its effects via receptors A and B. ET-1 and its receptors, endothelin axis (ET axis), play a promoting role in cancer biology. Alterations of proteins of ET axis ... -
Oral Phosphodiesterase Type 5 Inhibitors Alleviate Recurrent Priapism Complicating Thalassemia Intermedia: A Case Report
Tzortzis, V.; Mitrakas, L.; Gravas, S.; Mamoulakis, C.; Meissner, A.; Kyriakou, D.; Melekos, M. D. (2009)Introduction. Recurrent ischemic priapism still remains a serious and difficult to treat complication of certain hematological disorders. Elucidation of the underlying pathophysiologic mechanisms and application of new ... -
Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG
Zachos, I.; Tzortzis, V.; Mitrakas, L.; Samarinas, M.; Karatzas, A.; Gravas, S.; Vandoros, G. P.; Melekos, M. D.; Papavassiliou, A. G. (2014)We conducted a retrospective study to determine the prognostic significance of age, gender, associated carcinoma in situ, stage, number of tumors, and tumor size for patients with high-risk non-muscle-invasive bladder ...